An evidence-based approach to minimise contrast-induced nephropathy

New Zealand Medical Journal

Volumn 122, Issue 1299, 2009, Pages 39-41

  Darwish, Tarek ^a  

^a TRUMAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CREATININE; FENOLDOPAM; GADOLINIUM; IODINATED CONTRAST MEDIUM; SODIUM CHLORIDE; THEOPHYLLINE;

ARTICLE; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FLUID THERAPY; HUMAN; INCIDENCE; INTERVENTIONAL RADIOLOGY; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; NEPHROGENIC SYSTEMIC FIBROSIS; RISK FACTOR;

CONTRAST MEDIA; DIAGNOSTIC IMAGING; EVIDENCE-BASED MEDICINE; HUMANS; IODINE; KIDNEY DISEASES; RISK FACTORS;

EID: 68149183635     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. The New England journal of medicine 2006;354(4):379-86.
2. Rudnick MR, Kesselheim A, Goldfarb S. Contrast-induced nephropathy: How it develops, how to prevent it. Cleveland Clinic journal of medicine 2006;73(1):75-80, 3-7.
3. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA 2006;295(23):2765-79.
4. Cramer BC, Parfrey PS, Hutchinson TA, et al. Renal function following infusion of radiologic contrast material. A prospective controlled study. Archives of internal medicine 1985;145(1):87-9.
5. Heller CA, Knapp J, Halliday J, et al. Failure to demonstrate contrast nephrotoxicity. The Medical journal of Australia 1991;155(5):329-32.
6. Newhouse JH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: Implications for studies of contrast nephrotoxicity. AJR 2008;191(2):376-82.
7. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000;11(1):177-82.
8. Dussol B, Morange S, Loundoun A, et al. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 2006;21(8):2120-6.
9. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004;291(19):2328-34.
10. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney international 2004;65(4):1366-74.
11. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. The New England journal of medicine 2006;354(26):2773-82.
12. Cowper SE. Nephrogenic systemic fibrosis: The nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005;46(4):763-5.
13. Ergun I, Keven K, Uruc I, et al. The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 2006;21(3):697-700.